0001209191-22-005886.txt : 20220201
0001209191-22-005886.hdr.sgml : 20220201
20220201160607
ACCESSION NUMBER: 0001209191-22-005886
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220128
FILED AS OF DATE: 20220201
DATE AS OF CHANGE: 20220201
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stuart Nancy
CENTRAL INDEX KEY: 0001594774
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36310
FILM NUMBER: 22578945
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 500
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CONCERT PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001367920
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 65 HAYDEN AVENUE
STREET 2: SUITE 3000N
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-860-0045
MAIL ADDRESS:
STREET 1: 65 HAYDEN AVENUE
STREET 2: SUITE 3000N
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: CONCERT PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060628
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-28
0
0001367920
CONCERT PHARMACEUTICALS, INC.
CNCE
0001594774
Stuart Nancy
C/O CONCERT PHARMACEUTICALS, INC.
65 HAYDEN AVENUE, SUITE 3000N
LEXINGTON
MA
02421
0
1
0
0
Chief Operating Officer
Common Stock
2022-01-28
4
A
0
99000
A
269386
D
Common Stock
2022-01-28
4
A
0
21400
A
290786
D
Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in equal annual installments over a three-year period measured from the date of grant. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant.
Not applicable.
Represents a grant of RSUs. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest one business day after the date on which the Food and Drug Administration notifies the Issuer that it has accepted for filing a New Drug Application for CTP-543, provided that the date of acceptance is on or before a certain date in 2023. The amount listed represents the maximum number of shares that may be delivered pursuant to the grant.
/s/ Jeffrey A. Munsie, attorney-in-fact
2022-02-01